Quarterly report pursuant to Section 13 or 15(d)

FDA Refund

v3.20.1
FDA Refund
6 Months Ended
Mar. 31, 2020
FDA Refund [Abstract]  
FDA REFUND

8. FDA REFUND

 

In November 2019, the Company received an additional $110,207 refund from the FDA for 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA's review of the associated applications. The Company recorded the $110,207 as other income during the six months ended March 31, 2020.